City of Hope and Sorrento Therapeutics Inc. formed a company, LA Cell Inc., to focus on the development of cell-penetrating antibody therapies. LA Cell has exclusively licensed technology developed at City of Hope that enables modified monoclonal antibodies to penetrate into cells and target disease-causing molecules.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
